Skip to main content
OpenTrials

Clinical trial condition

Urological Manifestations

Explore clinical trials studying Urological Manifestations. Study availability and eligibility vary by location and protocol.

2,294 public trials 270 recruiting studies
Refine in advanced search Browse all conditions

Urological Manifestations trial results

Completed

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder

NCT01972841

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lower Urinary Tract Symptoms, +15 more
Locations
  • Site US10049 Coastal Clinical Research, Inc. Mobile, Alabama, United States
  • Site US10112 TFI, LLC Mobile, Alabama, United States
  • Site US10104 Clinical Research Advantage, Inc. Chandler, Arizona, United States
  • Site US10021 Beach Clinical Studies Phoenix, Arizona, United States
View all 435 locations
View Trial Details
Completed

A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug

NCT01565707

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lower Urinary Tract Symptoms, +8 more
Locations
  • Site: 1006 Shreveport, Louisiana, United States
  • Site: 1015 Albany, New York, United States
  • Site: 3202 Antwerp, Belgium
  • Site: 3209 Antwerp, Belgium
View all 46 locations
View Trial Details
Completed

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

NCT01908829

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lower Urinary Tract Symptoms, +11 more
Locations
  • Genova Clinical Research Tucson, Arizona, United States
  • Associated Pharmaceutical Research Center, Inc. Buena Park, California, United States
  • The American Institute of Research Los Angeles, California, United States
  • Bayview Research Group Valley Village, California, United States
View all 219 locations
View Trial Details
Completed

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder

NCT02045862

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lower Urinary Tract Symptoms, +15 more
Locations
  • Site US10049 Mobile, Alabama, United States
  • Site US10112 Mobile, Alabama, United States
  • Site US10104 Chandler, Arizona, United States
  • Site US10021 Phoenix, Arizona, United States
View all 251 locations
View Trial Details
Completed

A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice

NCT02320773

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lower Urinary Tract Symptoms, +11 more
Locations
  • Site CZ42009 UROMEDA s. r. o. Brno, Czechia
  • Site CZ42003 Fakultni nemocnice Brno-Bohunice Brno, Czechia
  • Site CZ42006 Hospital Kyjov Kyjov, Czechia
  • Site CZ42002 Fakultni nemocnice Kralovske Vinohrady Prague, Czechia
View all 60 locations
View Trial Details
Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)

NCT02526979

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lower Urinary Tract Symptoms, +10 more
Locations
  • Site DK45002 Aalborg, Denmark
  • Site DK45001 Aarhus, Denmark
  • Site PL48001 Warsaw, Poland
View Trial Details

Related conditions